Monoclonal antibodies (mAbs) have become one of the most important classes of
biopharmaceutical products, and they continue to dominate the universe of …

Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth
factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC) …

Over the last 3 decades, monoclonal antibodies have become the most important class of
therapeutic biologicals on the market. Development of therapeutic antibodies was …

Simple Summary Chemotherapy, radiotherapy and molecularly targeted therapy could
improve the prognosis of colorectal cancer (CRC) patients. Recently, immunotherapy …

Colorectal cancer (CRC) affects 1 in 23 males and 1 in 25 females, making it the third most
common cancer. With roughly 608000 deaths worldwide, CRC accounts for 8% of all cancer …

Antibodies as ideal therapeutic and diagnostic molecules are among the top-selling drugs
providing considerable efficacy in disease treatment, especially in cancer therapy …

Monoclonal antibody inhibitors of the epidermal growth factor receptor (EGFR) have been
shown to improve outcomes for patients with metastatic colorectal cancer (mCRC) without …

Background and purpose Colorectal cancer is a kind of gastrointestinal tumor with rising
morbidity and mortality. 5-fluorouracil is one of the most effective chemotherapy drugs for the …

Colorectal cancer (CRC) is one of the most lethal and common malignancies in the world.
Chemotherapy has been the conventional treatment for metastatic CRC (mCRC) patients …

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of
cancer deaths worldwide. Besides common therapeutic approaches, such as surgery …